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Abstract
Background: Asthma is a common chronic condition with an economic burden of almost $56 billion annually in
the US. Biologic markers like blood eosinophils, that help predict the risk of exacerbation could help guide more
optimal treatment plans and reduce cost. The purpose of this study was to determine whether healthcare resource
use and expenditures vary by eosinophil level among patients with asthma.
Methods: Patients with a diagnosis of asthma defined by ICD-9-CM code 493.xx between January 2004 and July
2011 were extracted from EMRClaims + database (eMAX Health, White Plains NY). Patients were classified as mild,
moderate, or severe by medication use following diagnosis, based on recommendations of National Institutes of
Health Expert Panel Report 3. Patients were classified as those with elevated eosinophils (≥400 cells/μL) and normal
eosinophil level (<400 cells/μL). Patients were followed for resource use, defined as hospitalizations, ER visits and
outpatient visit and associated costs were calculated to assess whether an economic difference exists between
eosinophil groups. Non-parametric tests were used to compare resource use and associated cost between elevated
and normal eosinophil groups. Multivariate modeling was performed to assess the contribution of eosinophil level
on the likelihood of study outcomes among patients with severe asthma.
Results: Among the 2,164 patients meeting eligibility criteria, 1,144 had severity designations. Of these, 179(16 %)
of patients had severe asthma of which 20 % (n = 35) had elevated eosinophils. Seventeen percent of patients with
elevated eosinophils were admitted to the hospital during the follow-up period, significantly greater than patients with
normal eosinophil levels (12 %; p = 0.011). Overall, compared to patients with normal eosinophil levels (n = 1734),
patients with elevated eosinophil levels (n = 430) had significantly greater mean annual hospital admissions (0.51 vs. 0.
21/year, p = 0.006) and hospital costs (2,536 vs. $1,091, p = 0.011). Logistic regressions showed that elevated eosinophil
level was associated with 5.14 times increased odds of all cause admissions (95 % CI:1.76–14.99, p = 0.003) and 4.07
times increased odds of asthma related admissions (95 % CI: 1.26–13.12, p = 0.019).
Conclusion: Eosinophil elevation was associated with greater healthcare resource use in patients with asthma.
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Background
Asthma has been reported to affect as many as 26 mil-
lion US adults with 51 % reporting asthma exacerbations
in 2011 [1]. In 2010 alone, there were over 400,000 per-
sons hospitalized in the US for asthma exacerbations [1].
In 2010, US patients with asthma logged over 10 million
physician office visits and over 2 million ER visits [1].
The overall annual economic burden caused by asthma
is as high as $564 billion, with 89 % in direct healthcare
cost [1].
In the overall burden caused by asthma, severe
asthma, specifically, results in a greater number of exac-
erbations, healthcare utilization, and expenditures [2].
Exacerbations among moderate and severe asthma
patients increase the frequency of hospital admissions by
nearly 50 %, and emergency department visits by 100 %,
compared to moderate and severe asthma patients with-
out exacerbations. This added healthcare utilization
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contributes to about $4000 increase in per patient cost
annually [3].
Patients with eosinophilic asthma (EA) are of particu-
lar concern since disease severity has been shown to cor-
relate with the level of eosinophils detected in blood and
the bronchoalveolar fluid [4]. When elevated, eosinophils
cause an immune-modulatory response which includes
airway inflammation and hyper responsiveness, damage
to epithelial lining, and excess secretion of mucus [5].
Sputum eosinophil levels are helpful in characterizing
airway inflammation, predicting response to corticosteroid
treatment, and identifying patients at risk of exacerbations
[5, 6]. However, sputum eosinophil measurements re-
quires specialized training to collect, process, and analyze
and is not generally available in clinical settings. Re-
searchers have reported a potential association between
fractional exhaled nitric oxide (FeNO) levels and eosino-
philic airway inflammation which may be helpful as a
non-invasive marker for EA in clinical practice [7]. We
have presented data showing an association between per-
ipheral blood eosinophilia and moderate-to-severe asthma
severity defined by Expert Panel-3 guidelines, given that
Complete Blood Count (CBC) with Differential tests are
routinely ordered for asthma patients [8]. However, it is not
clear whether elevated serum eosinophil level is associated
with a greater likelihood of hospitalization and elevated cost
in asthma patients. The objective of this study was to
understand the relationship between eosinophil level and
healthcare utilization and expenditures in patients with
asthma, as well the subset with severe asthma. Demon-
strated predictive value of eosinophils in asthma control
and system cost would support the utility of more focused
identification and management of this patient phenotype.
Methods
Study design and data source
We conducted a retrospective cohort analysis of US
asthma patients between January 2004 and July 2011.
Patients with a primary or secondary diagnosis of asthma
were followed to assess their resource use and cost. Data
was extracted from EMRClaims+, an integrated health
services database of patients located in the Midwest region
of the United States. The database includes administrative
insurance claims from a managed care plan of approxi-
mately 675,000 lives linked to an overlapping healthcare
provider database of electronic medical records data
(EMR), including laboratory values, and provider billing
files. The database also tracks commercially insured lives
through provider-aligned patient panels, managed care
membership files and a Master Patient Index.
Study population
All patients with at least two encounters in the inpatient
(to confirm asthma diagnosis), emergency room (ER), or
outpatient (OP) setting with an International Classifica-
tion of Diseases-9- Clinical Modification [ICD-9-CM]
code 493.xx as the primary or secondary diagnosis, were
selected. The date of the first asthma diagnosis during
the study period was defined as the index diagnosis date.
Patients less than 12 years of age at the time of index
diagnosis were excluded. Patients were required to be
continuously enrolled for a period of at least 13 months
after the index date, consisting of a 12 month ‘assess-
ment period’ to establish severity classifications based on
medication use and to record eosinophil test results, and
a follow-up of 1 to 12 months after this assessment
period during which outcomes were assessed. Patients
were excluded if during the assessment period: 1) they
had no eosinophil tests; 2) all eosinophil tests were con-
ducted while on systematic steroids (defined as eosino-
phil test dates overlapping with the periods of potential
systemic steroid use based on date of prescription fill,
days of supply of medication plus a 14 day washout
period) and the results were all under 400 cells/μL; this
exclusion criteria was to avoid including patients with
lower eosinophil values due to the effect of systemic
steroids [9]; or 3) if they had diagnoses of confounding
disease states of COPD, emphysema, Churg Strauss
syndrome, Wegener’s granulomatosis, hypereosinophilic
syndrome, pulmonary fibrosis, allergic bronchopulmon-
ary aspergillosis and lung cancer (ICD-9-CM codes:
491.xx-492.xx, 494.xx-496.xx, 277.x, 162.x, 446.4, 288.3,
516.31, 515, 518.6).
Study Measures
The National Heart, Lung, and Blood Institute’s Expert
Panel Report 3: Guidelines for the Diagnosis and Man-
agement of Asthma (EPR-3) criteria were adapted to
classify patients into mild, moderate, and severe disease
based on the pattern of asthma medications (Table 1).
For example, patients with use of high dose inhaled
corticosteroids (ICS) and long acting beta agonists
(LABA) or a combination of the two and oral cortico-
steroids, at any point during the assessment period,
were classified as having severe asthma. Patients with
only low dose ICS use at any time during the entire as-
sessment period were classified as those with mild
asthma. Given the lack of ‘impairment’ measures such
as night time awakenings we restricted the definition of
‘severe’ patients to those taking high-dose ICS as de-
scribed in Table 1. Patients were classified by eosinophil
level as “elevated” if at least one eosinophil test result
in the assessment period was ≥ 400 cells/μL, or “nor-
mal” if none of the test results of a patient were ≥ 400
cells/μL. We selected this threshold based on results of
research reported in the literature that show an associ-
ation between eosinophil elevation and asthma severity
at a threshold of ≥400 cells/μL [8, 10–12]. Consistent
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with data we have previously reported [8], Price and
colleagues (2015) assessed the effect of eosinophils at
lower cut-off values (≥200, ≥300 cells/μL) and found
very weak to no associations with future exacerbations
[10]. Patient demographics (age, gender, and race/ethni-
city) were recorded. Patients’ comorbidity burden was
measured using the Charlson Comorbidity Index (CCI).
Resource use, defined as hospital admissions, emer-
gency room (ER) visits and outpatient visits, and costs
associated with resource were estimated during the post-
assessment follow-up period. There were two sources of
cost data in this database: encounters from Plan-owned
sites, and external claims. For external claims, the claim
amounts were included as costs. Plan-owned sites
reported charges (since claims are not paid) from the ad-
ministrative charge master. These charges were reduced
to costs by multiplying the reported charges by a cost-
to-charge ratio factor of 0.33 (derived from 2,158
asthma encounters). This factor was calculated using
the Premier hospital database [13, 14], by comparing
actual costs to reported charges from 95 different hos-
pitals in Midwestern United States across nearly 13,000
encounters for patients diagnosed with asthma, with
2,158 asthma-related encounters (primary diagnosis).
Frequency of ER visits, outpatient visits, and hospital
admissions were also recorded. Annualized resource
utilization and cost were also calculated by multiplying
per patient per month (PPPM) values by 12.
Data analysis
The PPPM resource utilization as well as mean costs
among patients with asthma, identified in this study,
were compared between those with normal eosinophil
level vs. elevated eosinophil level. The statistical signifi-
cance of the mean differences was evaluated using non-
parametric tests. We used Chi-Square and Fisher Exact
test to compare the proportion of patients who had each
type of service use between patients with elevated eosin-
ophils versus those with normal eosinophils. In the ad-
justed analysis, logistic regressions were used to assess
the probability of resource consumption with eosinophil
level as the key independent (predictor) variable. The
models adjusted for other factors such as patient demo-
graphics, severity and CCI score. To account for differ-
ential follow-up time, weighted models based on the
number of months in each patient’s post-assessment
follow-up period were used. All data analyses were per-
formed using SAS software, version 9.3 (SAS Institute
Inc., Cary, North Carolina).
Results
A total of 2,164 patients met the eligibility criteria, of
whom 430 (16.5 %) had elevated eosinophil levels. A
total of 1,144 were classified into the three severity
groups with mild (40 %), moderate (44 %) and severe
(16 %) asthma. Among severe patients, no significant
differences in baseline patient characteristics were found
between elevated and normal eosinophil levels (Table 2).
The mean follow-up time for the patients with elevated
and normal eosinophils in the overall sample (2,164) as
well as among patients with severe asthma (179) was
11 months.
All asthma patients (n = 2,164)
Comparing mean unadjusted PPPM healthcare
utilization between the elevated and normal eosinophil
groups overall (n = 2,164) (Fig. 1) showed monthly all-
cause hospitalizations were significantly greater in the
elevated group (0.043 vs. 0.017, p = 0.006; annually 0.513
vs. 0.207, p = 0.006). Irrespective of severity, 17 % per-
cent of patients with elevated eosinophils were admitted
to the hospital during the follow-up period, significantly
greater than patients with normal eosinophil levels
(12 %; p = 0.011, Table 3). Mean monthly admission cost
was 2.3 times greater for the elevated eosinophilia group
(Fig. 1, annually $2,536 vs. $1,091, p = 0.011).
Severe asthma patients (n = 179)
Among patients with severe disease, both frequency and
proportion of hospitalization were significantly greater
for the elevated eosinophil group, with 4.6 times as
many monthly hospital admissions per patient (0.046 vs.
0.010, p = 0.001, Fig. 2), and more than 3.5 times as
many patients with at least one admission (29 % versus
8 %, Chi square p = 0.003, Table 3). No significant differ-
ences between the eosinophil groups for the number of
outpatient and ER claims were detected. Mean monthly
admission cost was significantly greater in the elevated
eosinophil group for all-cause admissions (p = 0.002,
Fig. 2). Annualized, the mean difference between ele-
vated and normal eosinophil groups for severe asthma
Table 1 Definition of severity levels based on medication use
Severity level Medications
Mild •Low dose ICS or
•Cromolyn, LTRA, nedocromil, or theophylline
Moderate •Low-dose ICS + LABA OR Medium-dose ICS
OR Medium-dose ICS + LABA, or
•Low-dose ICS + either LeukoTriene Receptor
Antagonist (LTRA),Theophylline, or Zileuton, or
•Medium-dose ICS + either LTRA, Theophylline,
or Zileuton
Severe •High-dose ICS + LABA OR High-dose ICS +
LABA + oral corticosteroid,or
•High-dose ICS + LABA + _Omalizumab, or
High-dose ICS + LABA + oral corticosteroid
+ Omalizumab
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was estimated at $1,310 ($2,410 vs. $1,100, p = 0.002).
Elevated eosinophil level increased the odds of all-cause
admissions (OR = 5.14, 95 % CI: 1.76–14.99, p = 0.003,
Fig. 3) as well as asthma related admissions (OR: 4.07,
95%CI: 1.26–13.12, p = 0.019) during follow-up.
Discussion
Our study found that patients with severe asthma and
elevated eosinophils at ≥400 cells/μL had a significantly
greater number of unadjusted monthly all cause hospital
admissions. Patients with elevated eosinophils were ad-
mitted to the hospital on average about once every
2 years, whereas patients with normal eosinophils were
admitted about once every 5 years. Similarly, patients
with severe asthma and elevated eosinophils were admit-
ted to the hospital about once every 1.8 years, whereas
patients with severe asthma and normal eosinophils
were admitted only about once every 8.3 years. These
Table 2 Demographic and comorbidity distribution- Patients with Severe Asthma
Patient characteristics Eosinophil level P
Elevated eosinophils (n = 35) Normal eosinophils (n = 144)
N (%) N (%)
Gender 0.953
Female 24 (68.6) 98 (68.1)
Race 0.608
White 20 (57.1) 74 (51.4)
Black 5 (14.3) 14 (9.7)
Hispanic 5 (14.3) 34 (23.6)
Other/Unknown 5 (14.3) 22 (15.3)
Age groups 0.165
12–17 years 2 (5.71) 5 (3.5)
18–35 years 8 (22.86) 18(12.50)
36–64 years 16 (45.71) 92(63.89)
Greater than/equal to 65 years 9 (25.71) 29 (20.14)
Top 5 Comorbidities
Diabetes 7 (20.0) 24 (16.7) 0.640
Cancer/tumor 3 (8.6) 7 (4.9) 0.413
Congestive Heart Failure 4 (11.4) 7 (4.9) 0.229
Cerebrovascular disease 0 (0.0) 3 (2.1) 1
Renal disease 2 (5.71) 1 (0.7) 0.098
Fig. 1 Mean Per Patient Per Month Utilization and Cost-Overall (n = 2,164)
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findings suggest that serum eosinophil levels can be used
to risk-stratify patients with asthma both overall and in
the subset with severe asthma. We did not find signifi-
cantly greater outpatient and ER visits for the elevated
eosinophil group. This indicates a stronger association
between eosinophil elevation and risk of severe exacer-
bations needing hospitalization, but not milder exacerba-
tions that required only an ER visit or clinic visit. This
difference could be explained by less successful thera-
peutic intervention with eosinophilia once in a state of
exacerbation. The more costly hospital admissions were
significantly greater, compared to normal eosinophil
group. More frequent hospitalization was responsible for
greater cost for the elevated eosinophil group. Adjusted
analyses show that severe asthma patients with elevated
eosinophils were significantly more likely to be admitted
to the hospital compared to patients with normal eosin-
ophils. To estimate the added cost to the U.S. of severe
asthma patients with elevated eosinophils (versus normal
eosinophils), we applied the proportion of severe disease
and elevated eosinophils we have observed here (16 and
19 % respectively) to the 26 million asthma patients.
Given the mean difference in admission cost for this seg-
ment (over $1,300), we estimate the added cost to the
U.S. healthcare system attributable to this group is ap-
proximately $1.3 Billion.
Limitations
We employed an approximation of EPR-3 recommenda-
tions regarding medication use to classify disease sever-
ity, rather than symptom control, lung function, or risk
of exacerbations. Our method was an approximation be-
cause we did not identify the lowest dose of controller
required for control, but instead relied on sporadic use.
Our approach did not account for drug switching, poten-
tially resulting in misclassification of an unknown fraction
of patients, with lower severity than might actually be the
case. Additional cohort bias was introduced because, for
patients who were prescribed more medication than ne-
cessary to achieve asthma control, our approach misclassi-
fied patients with milder asthma as patients with more
severe disease. Number of prescription claims, not actual
prescription consumption, was utilized to assess medica-
tion use. However, medications were used to define sever-
ity and regardless of whether they actually took the
medications, prescribers considered them appropriate
given the patients’ level of severity. Patients might overuse
SABA instead of being adjusted for long-term control
medications which may lead to some misclassification.
Despite rigorous inclusion/exclusion criteria for sample
identification, oral corticosteroids can be used for diseases
other than asthma which may misclassify patients as ‘se-
vere’. All financial data are estimates of cost, not data from
Table 3 Proportion of Patients with Resource Utilization during Follow-up
Overall (n = 2,164) Patients with severe asthma (n = 179)
Resource use Elevated eosinophils Normal eosinophils P value Elevated eosinophils Normal eosinophils P value
(N = 430) (N = 1,734) (N = 35) (N = 144)
Hospital admissions 73(17) 214(12) 0.011 10(29) 12(8) 0.001
ER visits 156(36) 622(36) 0.874 11(31) 47(33) 0.891
OP visits 373(87) 1536(89) 0.290 34(97) 134(93) 0.366
Fig. 2 Mean Per Patient Per Month Utilization and Cost-Severe Asthma Patients (n = 179)
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actual transaction. For a portion of encounters we used a
cost-to-charge ratio because only charge data was re-
ported. However, the cost-to-charge ratio was derived em-
pirically from a large hospital sample for asthma patients
in the same geography as our study. Additionally, due to
case finding criteria, our regressions should be viewed in
the context of a resulting smaller sample size for the se-
vere group with elevated eosinophils.
Conclusion
An elevated eosinophil level of at least 400 cells/μL was
associated with greater resource use and estimated cost
in overall asthma patients as well as those with severe
asthma. Adjusted analysis showed that blood eosinophil
elevation was significant in predicting probability of
hospitalization among severe asthma patients on aver-
age, and the smaller group of severe asthma patients
with elevated eosinophils drive healthcare expenditures.
Our findings demonstrate the importance of further re-
search to establish peripheral blood eosinophil elevation
as a biomarker for disease control and overall healthcare
expenditures.
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